Liver functional impairment in myotonic dystrophy type 1

Takada, Hiroto; Kon, S.; Oyama, Y.; Kimura, Takashi; Nagahata, Fumiko

doi:10.1016/j.nmd.2016.06.394

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LDL was also higher in patients with DM1 when compared with control group [27,28,[58][59][60][62][63][64]68,69]. Whereas HDL was similar in both patients and control group [27,28,[58][59][60][62][63][64][65][66]68,69]. TAG levels were higher in patients with DM1 than control group [27,28,[56][57][58][59][60][62][63][64][65][66][67][68][69].…”

Section: Metabolic Dysfunction In Dm1mentioning

confidence: 81%

“…Whereas HDL was similar in both patients and control group [ 27 , 28 , 58 , 59 , 60 , 62 , 63 , 64 , 65 , 66 , 68 , 69 ]. TAG levels were higher in patients with DM1 than control group [ 27 , 28 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ]. Furthermore, from the 18 studies, 11 [ 27 , 55 , 57 , 59 , 60 , 61 , 62 , 64 , 65 , 68 , 70 ] showed a significant difference ( p ≤ 0.05) between patients with DM1 and controls ( Table S1 ); namely, higher levels of insulin [ 57 , 59 , 61 , 62 ], HOMA-IR [ 27 , 57 , 61 , 65 , 70 ], total cholesterol [ 55 , 57 , 60 , 65 ], LDL [ 60 , 68 ], TAG […”

Section: Metabolic Dysfunction In Dm1mentioning

confidence: 99%

“…LDL was also higher in patients with DM1 when compared with control group [ 27 , 28 , 58 , 59 , 60 , 62 , 63 , 64 , 68 , 69 ]. Whereas HDL was similar in both patients and control group [ 27 , 28 , 58 , 59 , 60 , 62 , 63 , 64 , 65 , 66 , 68 , 69 ]. TAG levels were higher in patients with DM1 than control group [ 27 , 28 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ].…”

Section: Metabolic Dysfunction In Dm1mentioning

confidence: 99%

“…Dyslipidemia is frequently observed in patients with DM1 [ 9 , 27 , 28 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 68 , 69 , 95 ]. It is a term used for lipid disorders from hyperlipidemia to hypolipidemia, which includes the elevation of plasma cholesterol, hypertriglyceridemia, low HDL, high LDL, and exceed visceral fat accumulation.…”

Section: Lipin Protein Familymentioning

confidence: 99%

“…Furthermore, insulin resistance and dyslipidemia in skeletal muscle are associated with inflammatory state in adipose tissue through recruiting MCP-1, TNFα, and other cytokines leading to increased free fatty acids causing a decreased TAG synthesis, accumulation of TAG and activated lipids with a long-chain of fatty acyl-CoA esters. Consequently, a disruption of mitochondrial function, and glucose transport in the skeletal muscle, liver, and pancreas is observed, thus triggering insulin resistance and dyslipidemia [ 9 , 69 , 129 ]. Interestingly, macrophages can express lipin-1, lipin-2, and lipin-3, thus lipin also has an important role in macrophage physiology and pathophysiology [ 135 , 136 ].…”

Section: Lipin Protein Familymentioning

confidence: 99%

See 4 more Smart Citations

Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin

Mateus

Martins

Nunes

et al. 2021

IJERPH

View full text Add to dashboard Cite

Myotonic dystrophy type 1 (DM1) is an autosomal dominant hereditary and multisystemic disease, characterized by progressive distal muscle weakness and myotonia. Despite huge efforts, the pathophysiological mechanisms underlying DM1 remain elusive. In this review, the metabolic alterations observed in patients with DM1 and their connection with lipin proteins are discussed. We start by briefly describing the epidemiology, the physiopathological and systemic features of DM1. The molecular mechanisms proposed for DM1 are explored and summarized. An overview of metabolic syndrome, dyslipidemia, and the summary of metabolic alterations observed in patients with DM1 are presented. Patients with DM1 present clinical evidence of metabolic alterations, namely increased levels of triacylglycerol and low-density lipoprotein, increased insulin and glucose levels, increased abdominal obesity, and low levels of high-density lipoprotein. These metabolic alterations may be associated with lipins, which are phosphatidate phosphatase enzymes that regulates the triacylglycerol levels, phospholipids, lipid signaling pathways, and are transcriptional co-activators. Furthermore, lipins are also important for autophagy, inflammasome activation and lipoproteins synthesis. We demonstrate the association of lipin with the metabolic alterations in patients with DM1, which supports further clinical studies and a proper exploration of lipin proteins as therapeutic targets for metabolic syndrome, which is important for controlling many diseases including DM1.

show abstract